ThermiRF® Continues its Expansion in Latin America; Announcing ThermiRF Approval in Argentina.
Buenos Aires, Argentina, December 18, 2017 – ThermiGen, LLC. Thermi®, announces regulatory clearance to market and distribute ThermiRF in Argentina. ThermiRF is a temperature-controlled radiofrequency platform using The Science of Heat and the Beauty of Control, the system presents a versatile solution for aesthetic applications.
Technoimagen S.A., an importer and distributor of medical equipment in Argentina; partners with Thermi as the newest affiliate to offer the Thermi platform worldwide. As the exclusive distributor of ThermiRF products in Argentina, Technoimagen joins the Thermi family in defining the flourishing worldwide Aesthetic and Womens’ Intimate Health markets. “Achieving clearance of our products in Argentina marks the latest expansion in South America, and a new milestone for us. We look forward to working with the team at Technoimagen”, says Vlad Paul-Blanc, President of Thermi.
Thermi looks forward to a long and successful partnership with physician customers in Argentina. The launch of ThermiRF platform and supported applications include ThermiVa®, ThermiSmooth® Face, ThermiRase® and ThermiTight®. This new technology, will help physicians broaden their aesthetic offering to patients seeking non-surgical aesthetic solutions. Physicians depend on Thermi’s continued innovation and support to keep patient customers feeling and looking their best!
For marketing information please contact Sheetal Davitt, V.P. Global Marketing or visit: http://www.thermi.com/
The Thermi flagship product is the ThermiRF®, Temperature Controlled Radio Frequency Generator System. Worldwide clearances include FDA clearance for dermatological and general surgical procedures for electrocoagulation and hemostasis, and to create lesions in nervous tissue. ThermiRF is CE marked for Electrocoagulation of Soft Tissue for Vulvovaginal Laxity. ThermiRF is an advanced technology which provides physicians a tool to deliver finely controlled thermal energy. It is a multi-use platform which uses proprietary hand pieces designed for specific medical applications and promotes increased patient safety and clinical effectiveness, while providing versatile solutions for physicians serving the Aesthetic and Women’s Health markets.
Thermi is the worldwide distributor of the Thermi250® technology, a body contouring device which employs temperature-controlled radio frequency using specially designed hand pieces for large and small body areas. The system helps physicians provide consistent clinical outcomes by delivering precise heating to the skin surface.
For more information, please visit www.thermi.com
Almirall is a global pharmaceutical company with a strong focus in Dermatology and Aesthetics with the mission of providing valuable medicines and medical devices to you and future generations. Our R&D is focused on Dermatology, with a wide range of programs including key indications. Through our innovative products, agreements and alliances, our work covers the entire drug value chain. Almirall is continually growing as a specialist company in a wide range of skin diseases, in order to cover our customers’ unmet needs.
Founded in 1943, headquartered in Barcelona, Spain, Almirall is listed on the Spanish Stock Exchange (ticker: ALM) and it has become a source of value creation for society due to its vision and the commitment of its long-standing major shareholders. In 2016, its revenues totaled 859.3 million euros and, with more than 2.000 employees, it has gradually built up a trusted presence across Europe, as well as in the US.
For more information, please visit www.almirall.com.
This document includes only summary information and does not intend to be comprehensive. Facts, figures and opinions contained herein, other than historical, are "forward-looking statements". These statements are based on currently available information and on best estimates and assumptions believed to be reasonable by the Company. These statements involve risks and uncertainties beyond the Company's control. Therefore, actual results may differ materially from those stated by such forward-looking statements. The Company expressly disclaims any obligation to review or update any forward-looking statements, targets or estimates contained in this document to reflect any change in the assumptions, events or circumstances on which such forward-looking statements are based unless so required by applicable law.